Core Viewpoint - The company, Baijin Life Sciences (01466), has received a conversion notice from bondholders regarding the exercise of convertible bonds, leading to the issuance of new shares [1] Group 1: Convertible Bonds and Share Issuance - On September 29, 2025, the company received a notice from bondholders to convert HKD 31.5 million of convertible bonds at a conversion price of HKD 0.2628 per share [1] - A total of 119.9 million shares will be issued, representing approximately 15.52% of the company's existing issued share capital and about 13.43% of the enlarged issued share capital post-conversion [1] - The new shares are scheduled to be allotted and issued to the bondholders on October 8, 2025 [1]

Core Viewpoint - The company Baijin Life Sciences (01466.HK) has announced the issuance of 120 million shares following the conversion of convertible bonds worth HKD 31.5 million at a conversion price of HKD 0.2628 per share, impacting its existing share capital structure significantly [1] Group 1 - The company received a conversion notice from bondholders on September 29, 2025, regarding the exercise of conversion rights attached to the convertible bonds [1] - The newly issued shares represent approximately 15.52% of the company's existing issued share capital and about 13.43% of the expanded issued share capital post-conversion [1] - The shares were allotted and issued to the bondholders on October 8, 2025 [1]

Core Viewpoint - Baijin Life Sciences (01466) announced the issuance of 119.9 million shares following the exercise of conversion rights attached to convertible bonds worth HKD 31.5 million at a conversion price of HKD 0.2628 per share [1] Group 1 - The company received a conversion notice from bondholders on September 29, 2025 [1] - The newly issued shares represent approximately 15.52% of the company's existing issued share capital and about 13.43% of the enlarged issued share capital after the issuance [1] - The shares were allocated and issued to bondholders on October 8, 2025 [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購股份之邀請或要約。 Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 茲提述(i) 佰金生命科學控股有限公司（「本公司」）日期為2023 年6月29 日、2023年 11月30日、2024年1月2日及2024年2月9日之公告（ 統稱「該等公告」）；及(ii)本公 司日期為2024年1月25日之通函（「該通函」），內容有關（ 其中包括 ）向Ketto Inform Limited（「 債 券 持 有 人 」）發 行 本 金 額 為 31,500,000 港 元 之 可 換 股 債 券（「 可 換 股 債 券」），作為收購Tonnett Julis Holdings Limited全部已發行股本之代價之一部分，有 關收購事項於202 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佰金生命科學控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01466 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.02 | HKD | | 200,000,000 | FF3 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Baijin Life Science Holdings Limited 佰 金 生 命 科 學 控 股 有 限 公 司 （股份代號： 1466） （於開曼群島註冊成立之有限公司） 於2025年9月30日舉行之股東週年大會投票表決結果 茲 提 述 佰 金 生 命 科 學 控 股 有 限 公 司（「 本 公 司 」）日 期 均 為 2025 年 8 月 22 日 之 通 函 （「通函」）及股東週年大會通告（「股東週年大會通告」）。除本公告另有界定者外， 本公告所用詞彙與通函及股東週年大會通告所界定者具有相同涵義。 董事會欣然宣佈，股東週年大會通告所載之決議案已於股東週年大會上以投票表 決方式獲股東正式通過。 本公司之香港股份過戶登記分處卓佳證券登記有限公司獲委任為於股東週年大會 上負責點票工作之監票員。有關所有提呈決議案之投票表決結果如下： ...

Group 1 - The core point of the article is that Baijin Life Sciences (stock code: 1466) announced a financing plan through a general authorization to issue 40,000,000 new shares, raising approximately HKD 19.2 million [1] - The subscription price for the new shares is HKD 0.48 per share, which represents a discount of about 14.29% compared to the closing price of HKD 0.56 on September 29, 2025, and a discount of approximately 10.45% compared to the average closing price of HKD 0.536 over the last five trading days prior to September 26, 2025 [1] - The newly issued shares will account for approximately 5.18% of the existing issued share capital and about 4.92% of the enlarged share capital upon completion [1] Group 2 - The net proceeds from this financing, estimated at around HKD 19.1 million after expenses, will be used to supplement the group's general working capital [1] - The issuance is based on a general authorization granted at the shareholders' meeting and is subject to approval from the Stock Exchange of Hong Kong for the listing and trading of the subscription shares, with completion expected within five business days after the conditions are met [1]

Core Viewpoint - Baijin Life Sciences (01466.HK) announced a subscription agreement to issue a total of 40 million shares at a subscription price of HKD 0.48 per share, representing approximately 4.92% of the company's enlarged share capital, with the subscription price reflecting a discount of about 14.29% from the closing price on September 29 [1] Financial Summary - The total amount raised from the subscription is approximately HKD 19.2 million, with the estimated net proceeds being around HKD 19.1 million [1] - The net proceeds from the subscription will be used for the company's general working capital [1]

Group 1 - The company, Baijin Life Sciences (01466), announced a subscription agreement to issue a total of 40 million shares at a subscription price of HKD 0.48 per share [1] - The subscription price represents a discount of approximately 14.29% compared to the closing price of HKD 0.56 per share on the date of the agreement [1] - The net proceeds from the subscription are approximately HKD 19.1 million, which will be used for the company's general working capital [1]

Group 1 - The company, Baijin Life Sciences (01466), announced a subscription agreement on September 29, 2025, to issue a total of 40 million shares at a subscription price of HKD 0.48 per share [1] - The subscription price represents a discount of approximately 14.29% compared to the closing price of HKD 0.56 per share on the Hong Kong Stock Exchange on the same date [1] - The net proceeds from the subscription are approximately HKD 19.1 million, which will be used for the company's general working capital [1]